
Non-Small Cell Lung Cancer FISH PANEL






MEGHAN LEO

Overview

- Lung Cancer
- NSCLC Mutations
- FISH
- FISH Procedure
- Break-apart Probes
- ALK
- ROS
- RET
- Amplification Probes
- MET


NON SMALL CELL LUNG CANCER (NSCLC)

- Fifth most common cancer
- Highest rate of cancer deaths
- Low survival rate





NSCLC Mutations

NSCLC by Histology




Squamous Cell Carcinoma






What is FISH?

Locates specific DNA sequences





FISH Procedure




Break-apart Probes

- Also known as translocation probes
- ALK, ROS1 & MET











ALK


- Anaplastic lymphoma kinase
- Mutation EML4-ALK fusion
- <40yrs, non-smoker, female, East Asian
- Alectinib & Crizotinib longer survival time
- FISH positive
 - Breaks ≥ 2 signal widths
 - Isolated orange signal(s) with fused signal
 - Above cut-off threshold











ROS1

SLC34A2

CD74

TPM3

ROS1

ROS1

ROS1


SLC34A2-ROS1 gene fusion

CD74-ROS1 gene fusion


TPM3 -ROS1 gene fusion


- Receptor tyrosine kinase activity
- Driver mutation
- Crizotinib great response
- FISH positive
 - Breaks ≥ 1 signal width
 - Isolated green signal(s) with fused signal
 - Above cut-off threshold


Figure 1: Kinase Inhibitor Selectivity Assessment of Currently Approved ALK Inhibitors




http://www.touchoncology.com/articles/adverse-event-management-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-0/page/1/0











RET

- Shown to fuse with 8 different genes
- Clinical trials underway
- FISH positive
 - Breaks ≥ 1 signal width
 - Above cut-off threshold




Amplification Probes


- Locus-specific probes
- Amplification determined by ratio and/or copy number





MET

- Tyrosine-protein kinases Met or hepatocyte growth factor receptor (HGFR)
- Proto-oncogene
- Amplification associated with poor prognosis
- Crizotinib
- FISH:
 - o Ratio ≥ 2
 - Copy number per cell ≥ 5









Acknowledgements

- Toni-Marie Rogers
- Vicky Nastevski
- Angela Kam
- o Dr. Owen Prall
- Dr. Christine Khoo
- Dr. Christopher Angel
- NHC Organising Committee
- NHC Attendees

REFERENCES

- Rogers et al., Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. J Thorac Oncol 2015; 10:611-618
- Takeuchi et al., RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;3:378-381
- Beau-Faller et al., MET Gene Copy Number in Non-small Cell Lung cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort. J Thorac Oncol 2008; 4:331-339

